Meet Dr. Julie Brahmer

Global thought leader in the emerging field of immunotherapy

Dr. Brahmer’s research and clinical practice focus on the development of new therapies, including immunotherapies, for the treatment and prevention of lung cancer and mesothelioma. She was involved in the phase 1 trial of the PD-1 blocking antibody, nivolumab.
Dr. Brahmer is the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Director, Thoracic Oncology Program and Associate Professor of Oncology.

photo of Dr Julie Brahmer


Much of Dr. Brahmer’s work is in the new and exciting field of immunotherapy for lung cancer. This emerging treatment protocol uses a person’s own immune response to treat their disease.

Clinical Trials

No treatment is approved by the Federal Drug Administration (FDA) without first going through a clinical trial. Without clinical trials, there is no advancement in the science that produces life saving treatments.


More people are living with lung cancer.

Research advances like those highlighted in our Hope With Answers℠ video series are the key.


Learn more about what's new in lung cancer research

Finding reliable sources for information can be difficult for lung cancer patients – LCFA keeps you updated.


New lung cancer research is saving more lives.

Stand with survivors and help fund lung cancer research. By donating to LCFA, you help to fund innovative new research in the field of lung cancer treatment.